V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005057 | 10003160 | 1.78 | 83 | Palliative (P) | null | 2017-12-15 | DA 3 + 10 | 99 | N | 10563385 | CAPECITABINE + CARBOPLATIN |
| 10005058 | 10003160 | 1.67 | 87 | Palliative (P) | 2019-01-04 | 2019-01-05 | Capecitabine + Mitomycin | N | N | 10563385 | RUXOLITINIB |
| 10005059 | 10003160 | null | null | Palliative (P) | 2013-08-09 | 2013-08-10 | Capecitabine (21days) + Carboplatin | N | N | 10563385 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN |
| 10005060 | 10003161 | null | 65.4 | Disease modification (D) | 2014-06-08 | 2014-06-08 | TRASTUZUMAB | N | null | 10563425 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005061 | 10003162 | 1.76 | 59.9 | Curative (C) | 2015-10-30 | 2015-10-31 | Carboplatin + Docetaxel | 2 | N | 10563459 | CYTARABINE |
| 10005062 | 10003163 | 1.84 | 0 | Disease modification (D) | 2017-05-11 | 2017-05-11 | GEMCITABINE + NAB PACLITAXEL | N | Y | 10563628 | CYTARABINE |
| 10005063 | 10003164 | 1.75 | null | null | 2018-11-13 | 2018-11-28 | GEFITINIB | N | N | 10563630 | VEMURAFENIB |
| 10005064 | 10003165 | 1.56 | 53.45 | Curative (C) | 2019-01-03 | 2019-01-18 | CAPECITABINE + CISPLATIN + Trastuzumab | N | N | 10563698 | SUNITINIB |
| 10005065 | 10003166 | 1.65 | 62 | null | 2018-04-25 | 2018-04-25 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | Y | N | 10563801 | BORTEZOMIB + THALIDOMIDE |
| 10005066 | 10003167 | 1.7 | 64 | Curative (C) | 2017-06-18 | 2017-06-18 | EP | N | N | 10563888 | STAMPEDE TRIAL |
| 10005067 | 10003168 | 1.75 | null | Palliative (P) | 2016-12-20 | 2017-01-03 | Bendamustine +/- Prednisolone | Y | Y | 10564391 | FCR |
| 10005068 | 10006785 | 1.7 | 97.9 | Palliative (P) | 2013-12-07 | 2013-12-15 | EOF | N | N | 10564423 | CISPLATIN + FLUOROURACIL |
| 10005069 | 10006785 | 1.53 | null | Palliative (P) | 2018-10-19 | 2018-10-23 | CETUXIMAB + IRINOTECAN + MDG | 02 | Y | 10564423 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10005070 | 10003169 | 1.55 | 0 | Palliative (P) | 2016-01-13 | 2016-01-21 | MEDROXYPROGESTERONE | 02 | N | 10564461 | CETUXIMAB + IRINOTECAN + MDG |
| 10005071 | 10003170 | 1.78 | 77.7 | Palliative (P) | 2019-07-01 | 2019-07-04 | CETUXIMAB | N | N | 10075763 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 10005072 | 10003170 | 1.75 | 72.4 | Palliative (P) | 2018-03-15 | 2018-03-15 | CISPLATIN + FLUOROURACIL | N | N | 10075763 | CISPLATIN + FLUOROURACIL + RT |
| 10005073 | 10003171 | 1.7 | 90.3 | Palliative (P) | 2015-10-30 | 2015-11-16 | BEAM | N | N | 10155751 | CMV |
| 10005074 | 10003172 | 1.63 | 49.15 | Adjuvant (A) | null | 2019-09-11 | MITOMYCIN | 2 | N | 10190683 | MPV |
| 10005075 | 10006787 | 1.63 | 104 | Palliative (P) | 2015-01-19 | 2015-01-19 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | 10198488 | RAVVA TRIAL |
| 10005076 | 10006787 | null | 73 | Disease modification (D) | 2017-09-19 | 2017-09-24 | Sunitinib | N | null | 10198488 | CLADRIBINE |
| 10005077 | 10003173 | 1.9 | 81.8 | Disease modification (D) | 2017-10-11 | 2017-10-14 | Bevacizumab + Capecitabine | 02 | N | 10205861 | CAPECITABINE + IRINOTECAN |
| 10005078 | 10003173 | 0 | 84.4 | Adjuvant (A) | 2017-11-17 | 2017-11-18 | ECarboX | N | N | 10205861 | INCA TRIAL |
| 10005079 | 10003174 | 1.74 | null | Unknown (U) | 2015-12-27 | 2016-01-02 | Pemetrexed | N | N | 10213056 | REMODL TRIAL |
| 10005080 | 10006789 | 1.6 | 55.5 | null | 2015-01-29 | 2015-02-22 | MIC | 02 | N | 10213823 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005081 | 10003175 | 1.51 | 0 | Curative (C) | 2019-07-19 | 2019-07-22 | CYCLOPHOSPHAMIDE | 02 | N | 10214453 | MITOMYCIN |
| 10005082 | 10003176 | null | 85.9 | Curative (C) | 2018-11-16 | 2018-11-18 | Sorafenib | 2 | N | 10214598 | DA |
| 10005083 | 10003177 | null | 90 | Curative (C) | 2017-07-05 | 2017-07-05 | TEMOZOLOMIDE | N | N | 10215119 | PALBOCICLIB |
| 10005084 | 10003177 | 1.66 | 93 | Palliative (P) | 2017-12-10 | 2017-12-13 | Cytarabine Low Dose | 2 | N | 10215119 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10005085 | 10003178 | 1.7 | 0 | Disease modification (D) | 2017-10-12 | 2017-10-13 | DABRAFENIB | N | N | 10222557 | SORAFENIB |
| 10005086 | 10006791 | 1.76 | 66 | Adjuvant (A) | 2014-09-26 | 2014-10-02 | AML16 Azacitidine | 02 | N | 10223520 | VEMURAFENIB |
| 10005087 | 10003179 | null | null | Adjuvant (A) | 2015-11-12 | 2015-11-26 | NIVOLUMAB | N | N | 10225655 | MITOMYCIN INTRAVESICULAR |
| 10005088 | 10003179 | 1.7 | 85.8 | Curative (C) | 2017-09-16 | 2017-09-30 | CHLVPP | N | N | 10225655 | SORAFENIB |
| 10005089 | 10003180 | 1.73 | 92 | Curative (C) | null | 2017-11-14 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 1 | null | 10227056 | CISPLATIN + FLUOROURACIL |
| 10005090 | 10003181 | 0 | 0 | Curative (C) | 2018-07-16 | 2018-07-26 | Bexarotene | N | N | 10228121 | GEFITINIB |
| 10005091 | 10003182 | null | 80.2 | Palliative (P) | 2016-02-14 | 2016-02-24 | BALLAD Trial | 02 | N | 10229409 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10005092 | 10003182 | null | null | null | 2017-12-09 | 2017-12-16 | TCH (21 day Trastuzumab) Maint | 2 | N | 10229409 | VEPEMB |
| 10005093 | 10003182 | null | 67 | Palliative (P) | 2015-02-25 | 2015-03-01 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | 10229409 | EOF |
| 10005094 | 10003183 | 1.71 | 78.5 | Palliative (P) | 2019-04-24 | 2019-05-06 | DA 3 + 10 | N | N | 10233576 | CARBO + FLUOROURACIL |
| 10005095 | 10003184 | 1.83 | 102 | Palliative (P) | 2017-11-13 | 2017-11-14 | DABRAFENIB + TRAMETINIB | N | N | 10234621 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005096 | 10003184 | 1.75 | 82 | Palliative (P) | 2019-06-04 | 2019-06-05 | Mitomycin Intravesical | N | null | 10234621 | DOXORUBICIN + OLARATUMAB |
| 10005097 | 10003185 | 1.78 | 81.7 | Palliative (P) | 2018-06-17 | 2018-06-24 | MELPHALAN | 01 | N | 10234791 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005098 | 10003186 | 1.79 | 0 | Palliative (P) | 2018-07-11 | 2018-07-11 | GEMCITABINE + NAB PACLITAXEL | N | N | 10235688 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10005099 | 10003187 | 1.66 | 44.1 | Curative (C) | 2018-04-14 | 2018-04-17 | Cyclophosphamide + Docetaxel | N | N | 10236230 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10005100 | 10006795 | null | 90 | Palliative (P) | 2018-09-12 | 2018-09-13 | Trastuzumab 21 day loading dose | 02 | N | 10236329 | CETUXIMAB |
| 10005101 | 10006795 | 1.7 | null | Disease modification (D) | 2017-03-05 | 2017-03-19 | Sorafenib | N | N | 10236329 | BLEOMYCIN |
| 10005102 | 10003188 | 1.78 | 91.4 | Palliative (P) | null | 2017-08-15 | Dacarbazine | 02 | N | 10236915 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005103 | 10003188 | 1.67 | 77.1 | Palliative (P) | 2017-02-05 | 2017-02-12 | Mitomycin Intravesical | 02 | N | 10236915 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10005104 | 10003188 | 1.7 | null | Adjuvant (A) | 2019-05-22 | 2019-05-22 | Bevacizumab + CAPECITABINE + OXALIPLATIN | N | N | 10236915 | CAPECITABINE + CARBOPLATIN |
| 10005105 | 10003189 | 1.7 | 0 | Palliative (P) | 2018-03-15 | 2018-05-07 | Melphalan IV High dose | N | N | 10240541 | BORTEZOMIB + THALIDOMIDE |
| 10005106 | 10003189 | 1.71 | 63.5 | Curative (C) | 2017-10-06 | 2017-10-29 | CHOEP | N | N | 10240541 | BORTEZOMIB + THALIDOMIDE |